BiovaxID™ idiotype vaccination: active immunotherapy for follicular lymphoma

Abstract

Although advanced-stage follicular lymphoma (FL) has been considered incurable with standard therapy, novel strategies that utilize immunotherapy provide opportunities for prolonging disease-free survival. While passive immunotherapy with antibodies targeting the CD20 antigen on B cells has been the most widely applied lymphoma immunotherapy, active immunization with vaccines derived from the immunoglobulin idiotype present on the surface of FL provides an opportunity to induce specific humoral and cellular immune responses to the tumor, and have been demonstrated to produce significant benefits in prolonging disease-free survival. Promoting the benefits of all forms of immunotherapy will likely depend upon improving complete remission rates with initial treatment. BiovaxID™, a patient-specific idiotype vaccine, has demonstrated durable remissions when administered to FL patients in first complete remission along with keyhole limpet hemocyanin and granulocyte–macrophage colony-stimulating factor, and is now undergoing evaluation in a pivotal Phase III clinical trial.

Keywords::

• active
• cancer vaccine
• follicular
• immunoglobulin idiotypes
• immunology
• immunotherapy
• lymphoma
• therapy

Notes

DFS: Disease-free survival.